


Data Sheet

Product Name:	Foretinib
Cat. No.:	HY-10338
CAS No.:	849217-64-7
Molecular Formula:	C ₃₄ H ₃₄ F ₂ N ₄ O ₆
Molecular Weight:	632.65
Target:	c-Met/HGFR; VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Solubility:	DMSO: ≥ 38 mg/mL



BIOLOGICAL ACTIVITY:

Foretinib is an ATP-competitive inhibitor of **HGFR** and **VEGFR**, with **IC₅₀** of 0.4 nM and 0.9 nM for Met and KDR, less potent against Ron, Flt-1/3/4, Kit, PDGFR α/β and Tie-2, and has little activity to FGFR1 and EGFR.

IC₅₀ & Target: IC₅₀: 0.4 nM (Met), 0.9 nM (KDR)

In Vitro: Foretinib inhibits HGF receptor family tyrosine kinases with IC₅₀ values of 0.4 nM for Met and 3 nM for Ron. Foretinib also inhibits KDR, Flt-1, and Flt-4 with IC₅₀ values of 0.9 nM, 6.8 nM and 2.8 nM, respectively. Foretinib inhibits colony growth of B16F10, A549 and HT29 cells with IC₅₀ of 40 nM, 29 nM and 165 nM, respectively^[1]. A recent study indicates Foretinib affects cell growth differently in gastric cancer cell lines MKN-45 and KATO-III. Foretinib inhibits phosphorylation of MET and downstream signaling molecules in MKN-45 cells, while targets GFGR2 in KATO-III cells^[2].

In Vivo: Foretinib (100 mg/kg, p.o.) results in substantial inhibition of phosphorylation of B16F10 tumor Met and ligand (e.g., HGF α VEGF)-induced receptor phosphorylation of Met in liver and Flk-1/KDR in lung, which both persist through 24 hours. Foretinib (30-100 mg/kg, once daily, p.o.) results in reduction in tumor burden. The lung surface tumor burden is reduced by 50% and 58% following treatment with 30 and 100 mg/kg Foretinib, respectively. Foretinib treatment of mice bearing B16F10 solid tumors also results in dose-dependent tumor growth inhibition of 64% and 87% at 30 and 100 mg/kg, respectively. For both studies, administration of Foretinib is well tolerated with no significant body weight loss^[1]. Foretinib is developed to target abnormal signaling of HGF through Met and simultaneously target several receptors tyrosine kinase involved in tumor angiogenesis. Foretinib causes tumor hemorrhage and necrosis in human xenografts within 2 to 4 hours, and maximal tumornecrosis is observed at 96 hours (after five daily doses), resulting in complete regression^[3].

PROTOCOL (Extracted from published papers and Only for reference)

Kinase Assay: ^[1]Kinase inhibition is investigated using one of three assay formats: [³³P]phosphoryl transfer, luciferase-coupled chemiluminescence, or AlphaScreen tyrosine kinase technology. IC₅₀s are calculated by nonlinear regression analysis using XLFit.³³P-Phosphoryl Transfer Kinase Assay Reactions are performed in 384-well white, clear bottom, high-binding microtiter plates. Plates are coated with 2 μ g/well of protein or peptide substrate in a 50 μ L volume of coating buffer contained 40 μ g/mL substrate (poly(Glu, Tyr) 4:1, 22.5 mM Na₂CO₃, 27.5 mM NaHCO₃, 50 mM NaCl and 3 mM NaN₃). Coated plates are washed once with 50 μ L of assay buffer following overnight incubation at room temperature (RT). Test compounds and enzymes are combined with ³³P- γ -ATP (3.3 μ Ci/nmol) in a total volume of 20 μ L. The reaction mixture is incubated at RT for 2 hours and terminated by aspiration. The microtiter plates are subsequently washed 6 times with 0.05% Tween-PBS buffer (PBST). Scintillation fluid (50 μ L/well) is added and incorporated ³³P is measured by liquid scintillation spectrometry using a MicroBeta scintillation counter. Luciferase-Coupled Chemiluminescence Assay Reactions are conducted in 384-well white, medium binding microtiter plates. In a first step enzyme and compound are combined and incubated for 60 minutes; reactions are initiated by addition of ATP and peptide substrate (poly(Glu, Tyr) 4:1) in a final volume of 20 μ L,

and incubated at RT for 2–4 hours. Following the kinase reaction, a 20 μ L aliquot of Kinase Glo is added and luminescence signal is measured using a Victor plate reader. Total ATP consumption is limited to 50%. AlphaScreen™ Tyrosine Kinase Assay Donor beads coated with streptavidin and acceptor beads coated with PY100 anti-phosphotyrosine antibody are used. Biotinylated poly(Glu,Tyr) 4:1 is used as the substrate. Substrate phosphorylation is measured by addition of donor/acceptor beads by luminescence following donor–acceptor bead complex formation. Kinase and test compounds are combined and preincubated for 60 minutes, followed by addition of ATP, and biotinylated poly(Glu, Tyr) in a total volume of 20 μ L in 384–well white, medium binding microtiter plates. Reaction mixtures are incubated for 1 hour at room temperature. Reactions are quenched by addition of 10 μ L of 15–30 μ g/mL AlphaScreen bead suspension containing 75 mM Hepes, pH 7.4, 300 mM NaCl, 120 mM EDTA, 0.3% BSA and 0.03% Tween–20. After 2–16 hours incubation at room temperature plates are read using an AlphaQuest reader.

Cell Assay: [¹B16F10, A549, and HT29 cells (1.2×10^3 per well)) are mixed with soft agar and seeded in a 96–well plate containing 10% FBS and EXEL–2880 over a base agar layer. For normoxic conditions, the plates are incubated (37°C) for 12 to 14 days in 21% oxygen, 5% CO₂, and 74% nitrogen, whereas incubation (37°C) under hypoxic conditions is done in a hypoxia chamber in 1% oxygen, 5% CO₂, and 94% nitrogen. The number of colonies is evaluated under each condition following addition of 50% Alamar Blue and fluorescence detection.

Animal Administration: Foretinib is formulated in 0.9% normal saline.^[1] In vivo target modulation studies are done in naive mice or mice bearing B16F10 tumors. Foretinib or vehicle (0.9% normal saline) is administered at 10 mL/kg via oral gavage. For examination of Met phosphorylation in liver, HGF (10 μ g/mouse) is administered i.v. 10 min before harvest. For examination of Flk–1/KDR phosphorylation in lung, VEGF (10 μ g/mouse) is administered i.v. 30 min before harvest 0.5 h later. Receptor phosphorylation analysis is determined by immunoblot analysis.

References:

- [1]. Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL–2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. *Cancer Res*, 2009, 69(20), 8009–8016.
- [2]. Kataoka Y, et al. Foretinib (GSK1363089), a multi–kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter–receptor tyrosine kinase networks. *Invest New Drugs*, 2011.
- [3]. Eder JP, et al. A phase I study of foretinib, a multi–targeted inhibitor of c–Met and vascular endothelial growth factor receptor 2. *Clin Cancer Res*, 2010, 16(13), 3507–3516.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA